Science Department, World Anti-Doping Agency, P.O. Box 120, 800 Place Victoria, Montreal, Quebec, H4Z 1B7, Canada.
Forensic Sci Int. 2011 Dec 10;213(1-3):10-4. doi: 10.1016/j.forsciint.2011.06.001. Epub 2011 Jul 7.
Most substances used for doping in sport are legitimate pharmaceutical products deviated from their intended therapeutic applications. One of the major challenges for anti-doping authorities, in anticipation of future doping trends, is to assess the doping potential of drugs in development by the health industry and to timely develop anti-doping analytical methods to detect their abuse before such drugs become available to athletes intending to use them as doping agents. In this regard, the World Anti-Doping Agency (WADA) has recently consolidated several agreements with representatives from the pharmaceutical sector in order to establish a framework of collaboration and to facilitate the identification and transfer of information on drugs in development. The context of the collaborative effort between WADA and the pharmaceutical and biotechnology industries, as well as the role of drug regulatory agencies in an integrated process in support of the fight against doping in sport are described in this article.
大多数用于运动兴奋剂的物质都是从其预期的治疗用途中偏离出来的合法药物。为了应对未来的兴奋剂趋势,反兴奋剂机构面临的主要挑战之一是评估医药行业正在开发的药物的兴奋剂潜力,并及时开发反兴奋剂分析方法,在这些药物可供意图将其用作兴奋剂的运动员使用之前,检测它们的滥用情况。在这方面,世界反兴奋剂机构(WADA)最近与医药行业的代表达成了几项协议,以建立合作框架,并促进对正在开发的药物的识别和信息交流。本文介绍了 WADA 与医药和生物技术行业之间的合作努力的背景,以及药物监管机构在支持体育反兴奋剂斗争的综合过程中的作用。